```
* * * * * * * * * * *   Welcome to STN International   * * * * * * * * * * *
* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:21:22 ON 06 JUL 2008

=> file reg
=>Uploading C:\Program Files\Stnexp\Queries\Queries\10554061fi.str
```




```
chain nodes :
7  8  10
ring nodes :
1  2  3  4  5  6
chain bonds :
5-7  7-8  7-10
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
7-8
exact bonds :
5-7  7-10
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  10:CLASS

=> s l1 sam
L2            15 SEA SSS SAM L1

L3           21 L2

=>  Uploading C:\Program Files\Stnexp\Queries\Queries\10554061in.str
```




```
chain nodes :
13  14
```

```
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12
chain bonds :
5-13  9-13  13-14
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12
exact/norm bonds :
7-8  7-12  8-9  9-10  9-13  10-11  11-12  13-14
exact bonds :
5-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:CLASS  14:CLASS

=> s l4 full
L5          587 SEA SSS FUL L4

L6          181 L5

=> file caplus

=> s l3
L8           21 L2

=> s l8 and pd <april2003
      23714871 PD <APRIL2003
                 (PD<20030400)
L9           11 L8 AND PD <APRIL 2003

=> s l6
L10         181 L5

=> s l6 and pd< april 2003
      23714871 PD< APRIL 2003
                 (PD<20030400)
L11         100 L6 AND PD< APRIL 2003

=> s l8 and pd <april 2003
      23714871 PD <APRIL 2003
                 (PD<20030400)
L12          11 L8 AND PD <APRIL 2003

=> s l11 and l12
L13           0 L11 AND L12

=> dis l12 1-11 bib abs hitstr

L12  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2002:888735  CAPLUS  Full-text
DN   137:369971
TI   Preparation of substituted 4H-chromenes and analogs as activators of
     caspases and inducers of apoptosis and their uses against cancer and other
     disorders
IN   Cai, Sui Xiong; Zhang, Hong; Jiang, Songchun; Storer, Richard
```

PA Cytovia, Inc., USA
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092594	A1	20021121	WO 2002-US15399	20020516 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2447010	A1	20021121	CA 2002-2447010	20020516 <--
	AU 2002314781	A1	20021125	AU 2002-314781	20020516 <--
	US 20030065018	A1	20030403	US 2002-146138	20020516
	US 7053117	B2	20060530		
	EP 1392683	A1	20040303	EP 2002-741704	20020516
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1516700	A	20040728	CN 2002-812067	20020516
	JP 2004530692	T	20041007	JP 2002-589478	20020516
	US 20060035925	A1	20060216	US 2005-150586	20050613
PRAI	US 2001-290997P	P	20010516		
	US 1999-163584P	P	19991105		
	US 2000-185211P	P	20000224		
	US 2000-705840	A2	20001106		
	US 2002-146138	A1	20020516		
	WO 2002-US15399	W	20020516		

OS MARPAT 137:369971
GI



I

AB The present invention is directed to substituted 4H-chromenes and analogs thereof (shown as I; e.g. 2-amino-3-cyano-7-hydroxy-4-(3-bromo-4,5-dimethoxyphenyl)-4H-chromene). It also relates to the discovery that I are activators of caspases and inducers of apoptosis and, therefore, can be used to induce cell death in a variety of clin. conditions in which controlled growth and spread of abnormal cells occurs. In I: R1-R4 = H, halo, haloalkyl, aryl, fused aryl, carbocyclic, heterocyclic, heteroaryl, C1-10 alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido,

hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthio; or R1 and R2, or R2 and R3, or R3 and R4, taken together with the atoms to which they are attached form an aryl, heteroaryl, partially saturated carbocyclic or partially saturated heterocyclic group, wherein said group is optionally substituted. R5 is H or C1-10 alkyl; A is optionally substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl; Y is CN, COR7, CO2R7 or CONRxRy, wherein R7, Rx and Ry = H, C1-10 alkyl, haloalkyl, aryl, fused aryl, carbocyclic, heterocyclic, heteroaryl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or Rx and Ry are taken together with the N to which they are attached to form a heterocycle; and Z is NR8R9, NHCOR8, N(COR9)2, N(COR8)(COR9), N:CHOR8 or N:CHR8, wherein R8 and R9 = H, C1-4 alkyl or aryl, or R8 and R9 are combined together with the group attached to them to form a heterocycle. The EC50 values for >80 I against T-47D and ZR-75-1 human breast cancer cell lines are tabulated, e.g. 30 and 25 nM, resp., for 2-amino-3-cyano-4-(3-bromo-4,5-dimethoxyphenyl)-4H-indolo[7,6-b]pyran. Although the methods of preparation are not claimed, 81 example prepns. are included.

IT 70416-53-4, 5-Formylnicotinonitrile
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and their uses against cancer and other disorders)

RN 70416-53-4 CAPLUS
CN 3-Pyridinecarbonitrile, 5-formyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:220560 CAPLUS Full-text
DN 136:263098
TI Preparation of pyridinyl amides and imides for use as fungicides
IN Neubert, Timothy Donald; Piotrowski, David Walter; Walker, Michael Paul
PA E. I. Du Pont de Nemours & Co., USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002022583	A2	20020321	WO 2001-US28971	20010917 <--
WO 2002022583	A3	20020718		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002011233	A	20020326	AU 2002-11233	20010917 <--
	BR 2001014122	A	20030701	BR 2001-14122	20010917
	EP 1322614	A2	20030702	EP 2001-979248	20010917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004518629	T	20040624	JP 2002-526836	20010917
	CN 1688546	A	20051026	CN 2001-815519	20010917
	TW 238823	B	20050901	TW 2001-90123006	20010919
	ZA 2003000643	A	20040219	ZA 2003-643	20030123
	IN 2003MN00179	A	20050211	IN 2003-MN179	20030205
	US 20040044040	A1	20040304	US 2003-380243	20030312
	US 7074742	B2	20060711		
	MX 2003PA02338	A	20030910	MX 2003-PA2338	20030317
PRAI	US 2000-233374P	P	20000918		
	US 2001-277199P	P	20010320		
	WO 2001-US28971	W	20010917		

OS MARPAT 136:263098

GI



I

AB Title compds. [ACRR1R2YWB; A is a substituted pyridinyl ring; B is a substituted pyridinyl ring; W is C:L, SOn; L = O, S, CXR4; R1 and R2 are each independently = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, each optionally substituted; Y = NR3; R3 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl; R4 = C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, each optionally substituted; X = O, S; n = 1, 2; provided that when W is CO and R1, R2 and R3 are H; then B is other than 4-trifluoromethyl-3-pyridinyl, 2-chloro-4-pyridinyl and 2,6-dihalo-4-pyridinyl], N-oxides and agriculturally suitable salts are prepared and disclosed which are useful as fungicides. Also disclosed are compns. containing the compds. I and a method for controlling plant diseases caused by fungal plant pathogens that involves applying an effective amount of a compound I.

IT 134031-24-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridinyl amides and imides for use as fungicides)

RN 134031-24-6 CAPLUS

CN 3-Pyridinecarboxaldehyde, 2,4-dichloro- (CA INDEX NAME)



L12 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:85212 CAPLUS Full-text
DN 134:340420
TI Unusual chemoselective addition of diisopropylzinc to 2,2'-bipyridine-5,5'-dicarbonyl compounds in the 2-position and autoxidative reconversion with carbon-carbon bond cleavage
AU Tanji, Shigehisa; Shibata, Takanori; Sato, Itaru; Soai, Kenso
CS Department of Applied Chemistry, Faculty of Science, Science University of Tokyo, Kagurazaka, Shinjuku-ku, Tokyo, 162-8601, Japan
SO Journal of the Chemical Society, Perkin Transactions 1 (2001), (3), 217-218
CODEN: JCSPCE; ISSN: 1472-7781
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 134:340420
GI



AB Unusual chemoselective addition of diisopropylzinc to the 2-position of bipyridinedicarbonyl compds. I (R, R1 = CHO, CHO; CO2Me, CO2Me; Ac, Ac; CONMe2, CONMe2; H, CHO; H, CO2Me; H, Ac; H, CONMe2) gave the adducts II with a quaternary carbon. Autoxidn. of II reconverts them into the initial compds. I with carbon-carbon bond cleavage.
IT 338463-50-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(chemoselective addition of diisopropylzinc to bipyridinedicarbonyl compds. and autoxidn./carbon-carbon bond cleavage of dihydropyridylisopropylpyridines)
RN 338463-50-6 CAPLUS
CN [2,2'-Bipyridine]-5-carboxaldehyde, 5'-(1-hydroxy-2-methylpropyl)- (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:723594 CAPLUS Full-text
DN 132:58720
TI Potent, Orally Active GPIIb/IIIa Antagonists Containing a Nipecotic Acid Subunit. Structure-Activity Studies Leading to the Discovery of RWJ-53308
AU Hoekstra, William J.; Maryanoff, Bruce E.; Damiano, Bruce P.; Andrade-Gordon, Patricia; Cohen, Judith H.; Costanzo, Michael J.; Haertlein, Barbara J.; Hecker, Leonard R.; Hulshizer, Becky L.; Kauffman, Jack A.; Keane, Patricia; McComsey, David F.; Mitchell, John A.; Scott, Lorraine; Shah, Rekha D.; Yabut, Stephen C.
CS Drug Discovery and New Product Research, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA
SO Journal of Medicinal Chemistry (1999), 42(25), 5254-5265
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 132:58720
AB Although i.v. administered antiplatelet fibrinogen receptor (GPIIb/IIIa) antagonists have become established in the acute-care clin. setting for the prevention of thrombosis, orally administered drugs for chronic use are still under development. Herein, the authors present details from the authors exploration of structure-activity surrounding the prototype fibrinogen receptor antagonist RWJ-50042, which was derived from a unique approach involving the γ-chain of fibrinogen (Hoekstra et al. J. Med. Chemical 1995, 38, 1582). The authors analog studies culminated in the discovery of RWJ-53308 (I), a potent, orally active GPIIb/IIIa antagonist. To progress from RWJ-50042 to a suitable candidate for clin. development, the authors conducted a series of optimization cycles that employed solid-phase parallel synthesis for the rapid, efficient preparation of nearly 250 analogs, which were assayed for fibrinogen receptor affinity and inhibition of platelet aggregation induced by four different activators. This strategy produced several promising analogs for advanced study, including the 3-(3,4-methylenedioxybenzene)-β-amino acid analog (significant improved in vivo potency) and the 3-(3-pyridyl)-β-amino acid I (significantly improved potency, oral absorption, and duration of action). In dogs, I displayed significant ex vivo antiplatelet activity on oral administration at 1.0 mg/kg, 16% systemic oral bioavailability, minimal metabolic transformation, and an excellent safety profile. Addnl., I was efficacious in three in vivo thrombosis models: canine arteriovenous (AV) shunt (0.01-0.1 mg/kg, iv), guinea pig photoactivation-induced injury (0.3-3 mg/kg, iv), and guinea pig ferric chloride-induced injury (0.3-1 mg/kg, iv). On the basis of its noteworthy preclin. data, I was selected for clin. evaluation.
IT 252989-56-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit and structure-activity studies leading to discovery of RWJ-53308 as antiplatelet agent for treatment of thrombosis)
RN 252989-56-3 CAPLUS
CN 3-Pyridinecarboxaldehyde, 5-(2-phenylethynyl)- (CA INDEX NAME)



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:609624 CAPLUS Full-text
DN 127:262666
OREF 127:51301a,51304a
TI Naphthyridine derivatives, their methods of preparation and pharmaceutical compositions containing them, useful especially as antiproliferative drugs
IN Bru-Magniez, Nicole; Launay, Michele; Teulon, Jean-Marie
PA Laboratoires UPSA, Fr.
SO U.S., 11 pp., Cont.-in-part of U.S. 5,364,860.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5663181	A	19970902	US 1995-549665	19951129 <--
	FR 2706898	A1	19941230	FR 1993-7746	19930625 <--
	FR 2706898	B1	19950908		
	US 5364860	A	19941115	US 1993-97239	19930727 <--
	WO 9500513	A1	19950105	WO 1994-FR763	19940624 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9471275	A	19950117	AU 1994-71275	19940624 <--
	EP 705261	A1	19960410	EP 1994-920507	19940624 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08511793	T	19961210	JP 1994-502524	19940624 <--
	FI 9504982	A	19951227	FI 1995-4982	19951019 <--
PRAI	FR 1993-7746	A	19930625		
	US 1993-97239	A2	19930727		
	WO 1994-FR763	W	19940624		

OS MARPAT 127:262666
GI



I



II

AB The invention relates to title compds. I [X = H, halo; Y = O, S, NH; R, R1 = H, cyano, CO2R'; CONH2, CONH(CH2)nC6H4R'', NO2, pyridyl, halopyridyl, thiazolyl, alkylthiazolyl; or RR1 form indolin-2-one; R2 = alkyl, cycloalkyl, (CH2)mC6H3Z1Z2; m, n = 0-5; R' = H, alkyl; R'' = H, halo, alkyl; Z1, Z2 = H, alkyl, halo, CF3, OH, alkoxy, alkylthio, NO2, NH2, cyano] and their addition salts. The compds. are useful as drugs having antiproliferative properties, affording an effective treatment for diseases such as cancer, psoriasis, atherosclerosis, restenosis phenomena, or any other pathol. condition due to cell proliferation. For instance, condensation of 1-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-1,8-naphthyridine- 3-carboxaldehyde (preparation given) with 4-pyridylacetonitrile-HCl in EtOH in the presence of NaOEt gave 40% title compound II, a preferred compound In an assay for inhibition of PDGF-stimulated proliferation of balb c 3T3 fibroblasts in culture, II had an IC50 of 0.2 μM. Preliminary toxicol. studies showed good tolerance in rats at up to 300 mg/kg orally or i.p.

IT 195883-62-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of naphthyridine derivs. as antiproliferatives)

RN 195883-62-6 CAPLUS

CN 3-Pyridinecarboxaldehyde, 5-chloro-2-[(3,5-dichlorophenyl)amino]- (CA INDEX NAME)



L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1991:449586 CAPLUS Full-text

DN 115:49586

OREF 115:8612h,8613a

TI Lithiation of polychloropyrimidines and dichloropyridines

AU Radinov, R.; Chanev, Kh.; Khaimova, M.

CS Fac. Chem., Univ. Sofia, Sofia, 1126, Bulg.

SO Journal of Organic Chemistry (1991), 56(15), 4793-6
CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA English

OS CASREACT 115:49586

AB Polychloropyrimidines and -pyridines bearing halogens at activated ring positions can be regioselectively metalated with (Me2CH)2NLi or BuLi in THF at -80°. Lithiated heterocycles react with electrophiles to give adducts in high yield. The unusual C-4 selectivity of lithiation of 2,6-dichloropyridine with BuLi was studied. Trapping of lithiated intermediates with PhCHO and subsequent oxidation afforded useful heterocyclic building blocks.

IT 134031-24-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 134031-24-6 CAPLUS

CN 3-Pyridinecarboxaldehyde, 2,4-dichloro- (CA INDEX NAME)



L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1981:569014 CAPLUS Full-text
DN 95:169014
OREF 95:28249a,28252a
TI Pyridinyloxypropanolamines
IN Baldwin, John J.; Ponticello, Gerald S.
PA Merck and Co., Inc., USA
SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 866,961, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 4279913	A	19810721	US 1979-7092	19790129	<--
	JP 54106476	A	19790821	JP 1978-164500	19781229	<--
	DK 7900023	A	19790807	DK 1979-23	19790103	<--
	US 4294969	A	19811013	US 1980-167577	19800711	<--
	US 4393212	A	19830712	US 1981-263335	19810513	<--
PRAI	US 1978-866961	A2	19780104			
	US 1979-7092	A3	19790129			

OS CASREACT 95:169014
GI



I

AB Pyridinyloxypropanolamines I (n = 1, 2; R = C3-4 branched alkyl; R1 = H, acyl) were prepared for use as β-sympatholytics and antihypertensives (no data). Thus, cyclopentylidenemalononitrile was treated with HC(OEt)3 and cyclized with HBr-HOAc to give 57% 2-bromo-3- cyanocyclopenta[c]pyridine which was treated with (S)-2-phenyl-3-tert- butyl-5-hydroxymethyloxazolidine to give 35% I (R = CMe3, R1 = H, n = 1).
IT 70416-53-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 70416-53-4 CAPLUS
CN 3-Pyridinecarbonitrile, 5-formyl- (CA INDEX NAME)



L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1979:474426 CAPLUS Full-text
DN 91:74426
OREF 91:12029a,12032a
TI Functionalization of 5-methyl-2-halonicotinic acid derivatives
AU Ponticello, Gerald S.; Baldwin, John J.
CS Dep. Med. Chem., Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA
SO Journal of Organic Chemistry (1979), 44(15), 2702-4
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
AB Pyridines containing versatile functional groups in the 2, 3, and 5 positions were prepared via N-bromosuccinimide di- and tribrominations of the C-5 Me group of 2-halonicotinic acid derivs. Reductive dehalogenation of the 2-bromo substituent provides for a facile synthesis of unsym. pyridines in which the oxidation state of the C-3 and C-5 groups can be effectively controlled.
IT 70416-53-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 70416-53-4 CAPLUS
CN 3-Pyridinecarbonitrile, 5-formyl- (CA INDEX NAME)



L12 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1978:538018 CAPLUS Full-text
DN 89:138018
OREF 89:21249a,21252a
TI Moessbauer spectra of bidentate and monodentate carbonyl-substituted pyridine complexes of iron(II) dichlorides
AU Wei, Ho-Hsiang; Men, Lee-Chung
CS Dep. Chem., Tamkang Coll. Art Sci., Tamsui, Taiwan
SO Journal of Inorganic and Nuclear Chemistry (1978), 40(2), 221-4
CODEN: JINCAO; ISSN: 0022-1902
DT Journal
LA English
AB Thirteen complexes FeL2Cl2 (L = 2-, 3-, or 4-carbonyl-substituted pyridine) were prepared and characterized by Moessbauer and IR spectroscopy and magnetic moment measurements. FeL2Cl2 have distorted octahedral structures. The quadrupole splittings of the 2-substituted pyridine complexes are much larger than those of the 3- and 4-substituted pyridine complexes. The 2-substituted pyridines are bidentate whereas the 3- and 4-substituted pyridines are unidentate. The ground-state 3d orbital of the Fe in the complexes was shown to be dxy and the energy sepns. of the levels were estimated The effect of the substituent on the isomer shift of the complexes is discussed.
IT 65584-16-9P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and Moessbauer spectrum of)
RN 65584-16-9 CAPLUS
CN Iron, dichlorobis(3-pyridinecarboxaldehyde-N1)-, (T-4)-, homopolymer (9CI)

(CA INDEX NAME)

CM 1

CRN 65584-15-8
CMF C12 H10 Cl2 Fe N2 O2
CCI CCS



L12 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1978:82940 CAPLUS Full-text
DN 88:82940
OREF 88:12977a,12980a
TI Moessbauer spectra of bidentate and monodentate carbonyl-substituted pyridine complexes of iron(II) chlorides
AU Wei, Ho-Hsiang; Men, Lee-Chung
CS Dep. Chem., Tamkang Coll. Arts Sci., Tamsui, Taiwan
SO Proceedings of the National Science Council [Taiwan], Part 1, Natural and Mathematical Sciences (1977), 10, 161-73
CODEN: PNSSDV; ISSN: 0378-2727
DT Journal
LA English
AB FeL2Cl2, with pyridine derivs., RC5H4N(L; R = 2-, 3-, 4-MeCO, 2-, 3-, 4-PhCO, 2-, 3-, 4-H2NCO, 2- and 3-HO2C, 3- and 4-HCO), were prepared and characterized by chemical anal., Moessbauer and IR spectra, and magnetic measurements. The complexes have distorted octahedral structures. The magnitudes of the quadrupole splittings of the Moessbauer spectra for 2-substituted complexes are much larger than those of 3- or 4-substituted complexes since in the former the ligand is bidentate whereas in the latter it is monodentate. The ground state of 3d orbitals of Fe in the complexes was determined and the energy separation of t2g levels was estimated The effect on the isomer shift of different R groups in position 2 is discussed.
IT 65584-16-9P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and Moessbauer spectrum of)
RN 65584-16-9 CAPLUS
CN Iron, dichlorobis(3-pyridinecarboxaldehyde-N1)-, (T-4)-, homopolymer (9CI)
(CA INDEX NAME)

CM 1

CRN 65584-15-8
CMF C12 H10 Cl2 Fe N2 O2
CCI CCS



L12 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1971:53445 CAPLUS Full-text
DN 74:53445
OREF 74:8605a,8608a
TI Pyridines. VII. Hydration of diformylpyridines and their N-oxides
AU Queguiner, Guy; Salaun-Bouix, Michele; Pastour, Paul
CS Lab. Chim. Org., Inst. Nat. Super. Chim. Ind. Rouen, Mont-Saint-Aignan, Fr.
SO Bulletin de la Societe Chimique de France (1970), (10), 3690-7
CODEN: BSCFAS; ISSN: 0037-8968
DT Journal
LA French
AB The hydration of diformylpyridines and their N-oxides by D2O was studied by NMR spectrometry. Thus, the 3,5-, 2,4-, 2,5-, and 2,6-diformylpyridine N-oxides gave 40, 50, 65, and 75% dihydrate. The 2,3- and 3,4-diformylpyridine N-oxides were completely hydrated as cyclic hydrates.
IT 31198-35-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31198-35-3 CAPLUS
CN Nicotinaldehyde, 5-(dihydroxymethyl)- (8CI) (CA INDEX NAME)



=> log y
STN INTERNATIONAL LOGOFF AT 08:25:43 ON 06 JUL 2008